Inovio Pharmaceuticals PE Ratio 2006-2021 | INO

Current and historical p/e ratio for Inovio Pharmaceuticals (INO) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Inovio Pharmaceuticals PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Inovio Pharmaceuticals PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 7.02 0.00
2021-06-30 9.27 $-0.69 0.00
2021-03-31 9.28 $-1.13 0.00
2020-12-31 8.85 $-1.12 0.00
2020-09-30 11.60 $-1.36 0.00
2020-06-30 26.95 $-1.72 0.00
2020-03-31 7.44 $-1.19 0.00
2019-12-31 3.30 $-1.23 0.00
2019-09-30 2.05 $-1.19 0.00
2019-06-30 2.94 $-1.21 0.00
2019-03-31 3.73 $-0.99 0.00
2018-12-31 4.00 $-1.05 0.00
2018-09-30 5.56 $-0.95 0.00
2018-06-30 3.92 $-1.08 0.00
2018-03-31 4.71 $-1.13 0.00
2017-12-31 4.13 $-1.08 0.00
2017-09-30 6.34 $-1.20 0.00
2017-06-30 7.84 $-1.08 0.00
2017-03-31 6.62 $-1.21 0.00
2016-12-31 6.94 $-1.01 0.00
2016-09-30 9.32 $-0.90 0.00
2016-06-30 9.24 $-0.55 0.00
2016-03-31 8.71 $-0.38 0.00
2015-12-31 6.72 $-0.45 0.00
2015-09-30 5.78 $-0.32 0.00
2015-06-30 8.16 $-0.51 0.00
2015-03-31 8.16 $-0.61 0.00
2014-12-31 9.18 $-0.48 0.00
2014-09-30 9.85 $-0.64 0.00
2014-06-30 10.81 $-1.16 0.00
2014-03-31 13.32 $-1.21 0.00
2013-12-31 11.60 $-1.36 0.00
2013-09-30 8.28 $-1.08 0.00
2013-06-30 3.18 $-0.64 0.00
2013-03-31 2.38 $-0.52 0.00
2012-12-31 2.00 $-0.56 0.00
2012-09-30 2.34 $-0.72 0.00
2012-06-30 1.84 $-0.68 0.00
2012-03-31 2.68 $-0.64 0.00
2011-12-31 1.71 $-0.48 0.00
2011-09-30 2.26 $-0.56 0.00
2011-06-30 2.40 $-0.44 0.00
2011-03-31 4.40 $-0.64 0.00
2010-12-31 4.60 $-0.64 0.00
2010-09-30 5.00 $-0.68 0.00
2010-06-30 4.08 $-0.76 0.00
2010-03-31 5.28 $-1.24 0.00
2009-12-31 4.56 $-1.48 0.00
2009-09-30 6.28 $-1.52 0.00
2009-06-30 3.20 $-1.60 0.00
2009-03-31 1.56 $-1.20 0.00
2008-12-31 2.08 $-1.16 0.00
2008-09-30 2.48 $-0.92 0.00
2008-06-30 4.32 $-1.16 0.00
2008-03-31 3.84 $-1.24 0.00
2007-12-31 3.68 $-1.40 0.00
2007-09-30 5.40 $-1.92 0.00
2007-06-30 11.20 $-1.92 0.00
2007-03-31 12.96 $-1.88 0.00
2006-12-31 13.16 $-1.80 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.477B $0.007B
Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company's electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio's clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company's partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00